Home » Stocks » Tocagen

Tocagen Inc. (TOCA)

Jun 16, 2020 - TOCA merged into FBRX
Stock Price: $1.26 USD 0.00 (0.00%)
Updated Jun 15, 2020 4:00 PM EDT

Stock Price Chart

Key Info

Market Cap 30.14M
Revenue (ttm) 27,000
Net Income (ttm) -56.71M
Shares Out 1.59M
EPS (ttm) -2.38
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jun 15, 2020
Last Price $1.26
Previous Close $1.26
Change ($) 0.00
Change (%) 0.00%
Day's Open -
Day's Range 1.22 - 1.50
Day's Volume 0
52-Week Range 0.42 - 6.77

More Stats

Market Cap 30.14M
Enterprise Value 24.80M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 1.59M
Float 18.29M
EPS (basic) -2.37
EPS (diluted) -2.38
FCF / Share -2.03
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.47M
Short Ratio 3.06
Short % of Float 7.65%
Beta 0.00
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 1,116.22
PB Ratio 14.48
Revenue 27,000
Operating Income -53.34M
Net Income -56.71M
Free Cash Flow -48.48M
Net Cash 5.34M
Net Cash / Share 0.22
Gross Margin 133.33%
Operating Margin -197,544.44%
Profit Margin -210,044.40%
FCF Margin -179,566.67%
ROA -57.82%
ROE -241.66%
ROIC -150.40%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (1)

Buy 0
Overweight 0
Hold 1
Underweight 0
Sell 0
What these ratings mean

Analyst Consensus: Hold

Price Target

$15.00*
Low
15.0
Current: $1.26
High
15.0
Target: 15.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Income Statement | Balance Sheet | Cash Flow
Year20192018201720162015
Revenue0.0418.040.040.050.05
Revenue Growth-99.8%43890.24%-16.33%-3.92%-
Gross Profit0.0418.040.040.050.05
Operating Income-61.51-45.85-37.63-31.69-22.95
Net Income-63.52-48.96-38.93-33.48-23.06
Shares Outstanding23.6320.0614.612.202.18
Earnings Per Share-2.69-2.44-2.66-15.22-10.57
Operating Cash Flow-59.24-34.47-31.13-29.54-21.04
Capital Expenditures0.01-1.97-0.64-0.53-0.22
Free Cash Flow-59.23-36.44-31.77-30.06-21.26
Cash & Equivalents21.8296.0988.7331.2558.91
Total Debt8.7726.2010.8320.9817.47
Net Cash / Debt13.0569.8977.9010.2741.44
Assets28.1610392.0735.3562.18
Liabilities17.3144.9420.9928.3623.09
Book Value10.8558.1571.08-124-92.33
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Tocagen Inc.
Country United States
Employees 9
CEO Martin J. Duvall

Stock Information

Ticker Symbol TOCA
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: TOCA
IPO Date April 13, 2017

Description

Tocagen Inc., a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells. The company's lead product candidate is Toca 511 & Toca FC that is under Phase III clinical trial for recurrent high-grade glioma. It is also developing Toca 511 & Toca FC in a Phase Ib clinical trial for intravenous treatment of advanced cancers. In addition, the company is developing other RRVs to deliver genes to cancer cells against validated immunotherapy targets. The company has a license agreement with ApolloBio to develop and commercialize Toca 511 & Toca FC; and a collaboration agreement with NRG Oncology to develop a clinical trial utilizing Toca 511 & Toca FC for the treatment of patients with newly diagnosed glioblastoma. Tocagen Inc. was founded in 2007 and is based in San Diego, California.